PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 88 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 1.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $159,791 | -5.8% | 15,409 | +30.1% | 0.00% | 0.0% |
Q2 2023 | $169,635 | +100.7% | 11,846 | +0.1% | 0.00% | 0.0% |
Q1 2023 | $84,538 | -35.1% | 11,840 | +2.0% | 0.00% | 0.0% |
Q4 2022 | $130,197 | +7.6% | 11,604 | +6.1% | 0.00% | 0.0% |
Q3 2022 | $121,000 | +33.0% | 10,933 | +1.4% | 0.00% | 0.0% |
Q2 2022 | $91,000 | -33.6% | 10,778 | +7.2% | 0.00% | 0.0% |
Q1 2022 | $137,000 | -35.4% | 10,055 | -6.6% | 0.00% | 0.0% |
Q4 2021 | $212,000 | -40.4% | 10,763 | -2.9% | 0.00% | -50.0% |
Q3 2021 | $356,000 | -7.3% | 11,085 | -2.3% | 0.00% | +100.0% |
Q2 2021 | $384,000 | +51.8% | 11,348 | +68.2% | 0.00% | 0.0% |
Q1 2021 | $253,000 | +22.2% | 6,747 | +8.0% | 0.00% | 0.0% |
Q4 2020 | $207,000 | -12.3% | 6,245 | -2.8% | 0.00% | 0.0% |
Q3 2020 | $236,000 | +9.3% | 6,424 | -2.2% | 0.00% | 0.0% |
Q2 2020 | $216,000 | +31.7% | 6,570 | +3.1% | 0.00% | 0.0% |
Q1 2020 | $164,000 | -21.9% | 6,370 | -5.5% | 0.00% | 0.0% |
Q4 2019 | $210,000 | – | 6,738 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
FRAZIER MANAGEMENT LLC | 5,827,415 | $187,060,000 | 14.97% |
Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $66,378,000 | 14.44% |
Abingworth LLP | 1,203,135 | $38,512,000 | 8.74% |
Penn Mutual Asset Management, LLC | 86,940 | $2,791,000 | 4.41% |
GREAT POINT PARTNERS LLC | 220,863 | $7,090,000 | 1.65% |
RA Capital Management | 3,115,008 | $99,992,000 | 1.39% |
StepStone Group LP | 422,085 | $13,549,000 | 0.88% |
Summit Rock Advisors, LP | 34,100 | $1,094,000 | 0.65% |
Rhenman & Partners Asset Management AB | 186,210 | $5,977,000 | 0.42% |
Eventide Asset Management | 600,000 | $19,260,000 | 0.25% |